Anti-Migraine Drugs Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth And Forecast 2022 - 2027

Report Code: HCR 0150 Report Format: PDF + Excel

Anti-Migraine Drugs Market Overview

Anti-Migraine Drugs Market Size is estimated to reach $11.1 billion by 2027. Furthermore, it is poised to grow at a CAGR of 8.3% over the forecast period of 2022-2027. A migraine is a common neurological disorder that causes throbbing, pulsating headaches on one side of the head which varies in intensity. Tetracycline which is an antibiotic that works by stopping the growth of bacteria sometimes causes acute migraine attacks besides nausea, vomiting, diarrhea, and loss of appetite. Anti-migraine drugs are used to reduce the intensity of migraine headaches. Migraine headaches are sometimes preceded by warning symptoms called aura such as flashing lights or zigzag lines. Anti-nausea drugs are advised if migraine with aura is accompanied by nausea and vomiting. Drugs containing opioids such as oxycontin, Vicodin, Percocet, and so on prevent reversal of migraine central sensitization. The medications used in migraine treatment can be split into two categories: abortive and preventive. Abortive drugs are used to stop an existing migraine attack, while preventive drugs are intended to limit the number of migraine attacks. The rising prevalence of migraines, increase in healthcare expenditure and rising awareness about anti-migraine drugs are some of the factors driving the Anti-Migraine Drugs Market growth during the forecast period 2022-2027.

Report Coverage

The report: “Anti-Migraine Drugs Market Forecast (2022-2027)", by Industry ARC covers an in-depth analysis of the following segments of the Anti-Migraine Drugs Market.

By Drug Type- Abortive Medications: Triptans, Ergots, and Preventive Medications: Blood pressure-lowering Medications, Anticonvulsant Drugs, Calcitonin Gene-related Peptide (CGRP) Antagonists, Other Preventative Therapies

By End-User- Males and Females

By Route of Administration: Oral & nasal and Injectables

By Distribution Channel- Pharmaceutical stores, E-Commerce, and Others

By Geography- North America (U.S., Canada, Mexico), Europe (Germany, United Kingdom (U.K.), France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, Japan India, South Korea, Australia, and New Zealand, and Rest of Asia Pacific), South America (Brazil, Argentina, and Rest of South America), and Rest of the World (the Middle East, and Africa).

Key Takeaways

  • Geographically, North America held a dominant market share in the year 2021 owing to the increasing adoption of anti-migraine drugs owing to the growing prevalence of migraine cases. Asia-Pacific is expected to offer lucrative growth opportunities to the manufacturers owing to the rising awareness about the effectiveness of Anti-nausea drugs containing oxycontin. The robust growth of triptan and the development of novel drugs to cure migraine is predicted to augment the market growth during the forecast period of 2022-2027.
  • The increasing female population with a high risk of migraine is estimated to drive the market growth of anti-migraine drugs. Side effects of migraine and increasing competition in the market continue to pose threat to the market growth.
  • A detailed analysis of strengths, weaknesses, opportunities, and threats will be provided in the Anti-Migraine Drugs Market Report.

Anti-Migraine Drugs Market: Market Share (%) by Region, 2021


For more details on this report - Request for Sample

Anti-Migraine Drugs Market Segmentation Analysis- By Drug Type

Anti-Migraine Drugs Market based on drug type can be further segmented into Abortive and Preventive Medications. The sub-segment Triptans of Abortive segment held a dominant market share in the year 2021 and is estimated to be the fastest-growing, with a CAGR of 6.4% over the forecast period of 2022-2027. Anti-nausea drugs work by relaxing hyperactive nerves in the brain, which are triggered by migraines. They also aid in the stabilization of blood vessels. This aids in the relief of migraine symptoms. Oral triptans are better than oral ergots because the bioavailability oral of ergotamine is extremely low. Bioavailability is the ability of a drug or other substance to be absorbed and used by the body. Triptans are highly effective, lessens symptoms, or aborts an attack in 70–80% of patients within 30–90 minutes. Those with a history of, or risk factors for, heart disease, high blood pressure, high cholesterol, impaired liver function, stroke, or diabetes should avoid triptans. Increasing healthcare expenditure is estimated to propel market growth during the forecast period.

Anti-Migraine Drugs Market Segmentation Analysis- By End User

Anti-Migraine Drugs Market based on end-user can be further segmented into Males and Females. Females held a dominant market share in the year 2021 and are estimated to be the fastest-growing, with a CAGR of 5.9% over the forecast period of 2022-2027. According to Migraine Research Foundation, Women are three times more likely than males to suffer from migraines. In the U.S., 18% of women suffer from migraine compared to 6% of men. Hormonal changes are estimated to be the cause of migraines in approximately 70% of women. Estrogen is a hormone that regulates the female reproductive system as well as controls the chemicals in the brain that affect pain sensation. A drop in the level of estrogen can result in a headache, usually in the form of a migraine that lasts four to 72 hours. Usually, hormone fluctuations occur before menstruation, during pregnancy, after giving birth, during perimenopause and menopause, at times of anxiety and stress. The rising female population is predicted to augment the market growth of anti-migraine drugs over the forecast period 2022-2027.

Anti-Migraine Drugs Market Segmentation Analysis- By Geography

The Anti-Migraine Drugs market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America held a dominant market share of 41% in the year 2021 as compared to the other counterparts on account of the rising prevalence of migraine and increasing adoption of anti-migraine drugs & Anti-nausea drugs. According to American Migraine Association, migraine impacts over 37 million men, women, and children in the USA. One in four households has a member with migraine.

However, Asia-Pacific is estimated to be the fastest-growing, with a CAGR of 6.2% over the forecast period of 2022-2027 on account of an increase in demand for better healthcare facilities, raising awareness about the effectiveness of anti-migraine drugs, untapped investment potential, and rising prevalence of migraine. China is dominating and is estimated to dominate during the forecast period the Asia-Pacific migraine treatment market owing to its fastest-growing pharmaceutical industry. China’s government’s pharma policies and incentives devoted towards the reformation of the pharmaceutical industry are estimated to augment the market growth over the forecast period.

Anti-Migraine Drugs Market Drivers

  • The Increasing Prevalence of Migraine has benefitted the consumption of anti-migraine drugs

According to the World Health Organization (WHO), present migraine affects 10% of individuals worldwide, while lifetime migraine affects 1 in every 7 adults. Approximately 3000 migraine attacks per million persons worldwide occur every day and it is ranked as the 19th most common reason for disability by WHO. Factors such as increasing work pressure, anxiety, stress, and changes in lifestyles are some of the causes for the increasing prevalence of migraine globally. According to the American Migraine Foundation, if one of the parents has migraines, the child has a 50% chance of developing migraines as well. If both the parents suffer from migraine, chances increase to 75 percent. Migraines are primarily caused by a combination of genetic, environmental, and lifestyle factors. Migraines are painful, but for some people, auras associated with severe migraines may be a warning sign of a more serious problem, for instance, an increased risk of stroke, thereby driving the Anti-Migraine Drugs Industry.

  • Increased awareness of the Anti-migraine drug has readily aided the market growth.

The rise in public awareness regarding the use of anti-migraine drugs, as well as the expanding migraine population, are propelling the market for anti-migraine drugs forward. Many organizations are working towards spreading awareness about Anti-nausea drugs globally. For instance, in June 2021, the Coalition for Headache and Migraine Patients (CHAMP) organized National Migraine & Headache Awareness Month (MHAM) covering various aspects of migraine and its remedies. The National Headache Foundation, USA, a leader in headache and migraine awareness, launched its primary care migraine app where they collected the most comprehensive information on headache disorder and migraine disease and made them freely available to the public to raise awareness about it. The rapid penetration of medical services into rural regions and an increase in the development of novel drugs through R&D are estimated to augment the market growth during the forecast period of 2022-2027.

Anti-Migraine Drugs Market Challenges

  • Side Effects of Anti Migraine Drugs are impeding the market growth.

The side effects of anti-migraine drugs continue to pose threat to the market growth. Some of the common side effects are dizziness, drowsiness, feeling weak or tired, flushing, nausea, and so on. People who take migraine medication too often may find that their migraines getting worse and more frequent. Overuse of migraine medicines might result in a headache called Medication-Overuse Headache (MOH) or Rebound Headaches. The risk of getting a medication-overuse headache is considerably higher when these drugs are taken frequently over a long period of time which is at least three months than when they are taken over a shorter period of time.  Also, some of the anti-migraine drugs are not advised for people having a history of, or risk factors for, heart disease, high blood pressure, high cholesterol, impaired liver function, stroke, and so on as they temporarily narrow blood vessels restrain the Anti-Migraine Drugs market demand.

Anti-Migraine Drugs Market Competitive Landscape

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Anti-Migraine Drugs Market. The top 10- Anti-Migraine Drugs Market companies are-

  1. Eli Lilly 
  2. GlaxoSmithKline Plc
  3. AbbVie Pharmaceuticals
  4. Impax Laboratories Inc.
  5. Amgen
  6. Lundbeck
  7. Bristol-Myers Squibb Company
  8. Pfizer Inc
  9. AstraZeneca plc
  10. Endo International Inc

Recent Developments

  • In September 2021, FDA approved QULIPTA, the First and Only Oral CGRP Receptor Antagonist Specifically Developed for the Preventive Treatment of Migraine by AbbVie Pharmaceuticals. CGRP and its receptors are found in areas of the nervous system linked to migraine pathogenesis, and CGRP levels have been found to be higher during migraine attacks in studies. QULIPTA is a once-daily dose that blocks CGRP and comes in three strengths: 10 mg, 30 mg, and 60 mg.
  • In June 2021, Amgen announced the Approval of Aimovig (Erenumab) in Japan for The Suppression of Onset of Migraine Attacks in Adults by the Japanese Ministry of Health, Labour, and Welfare. It is Japan's First and Only Approved Treatment for Blocking the Calcitonin Gene-Related Peptide Receptor (CGRP-R), which is involved in migraine.
  • In October 2019, Lundbeck, a Danish global pharmaceutical business, acquired Alder BioPharmaceuticals, a pharmaceutical development company situated in Bothell, Washington. A migraine drug that Lundbeck added to its pipeline via its nearly $2 billion acquisition of Alder BioPharmaceuticals won FDA approval in February 2020. The drug blocks calcitonin gene-related peptide (CGRP), a protein associated with the onset of migraine pain

Relevant Titles 

Generic Drugs Market

Report Code: HCR 0217

Anti-Hypertensive Drugs Market

Report Code: HCR 0148

For more Lifescience and Healthcare related reports, please click here

1. Anti-Migraine Drugs Market - Overview
    1.1 Definitions and Scope
2. Anti-Migraine Drugs Market - Executive Summary
3. Anti-Migraine Drugs Market - Comparative Analysis
    3.1 Company Benchmarking
    3.2 Global Financial Analysis
    3.3 Market Share Analysis
    3.4 Patent Analysis
    3.5 Pricing Analysis
4. Anti-Migraine Drugs Market - Startup Companies Scenario Premium
    4.1 Key Startup Company Analysis by
        4.1.1 Investment
        4.1.2 Revenue
        4.1.3 Venture Capital and Funding Scenario
5. Anti-Migraine Drugs Market – Industry Market Entry Scenario Premium Premium
    5.1 Regulatory Framework Overview
    5.2 New Business and Ease of Doing Business Index
    5.3 Case Studies of Successful Ventures
6. Anti-Migraine Drugs Market - Forces
    6.1 Market Drivers
    6.2 Market Constraints/Challenges
    6.3 Porters Five Force Model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes
7. Anti-Migraine Drugs Market – Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle
8. Anti-Migraine Drugs Market – By Drug Type
    8.1 Abortive Medications
        8.1.1 Triptans
        8.1.2 Ergots
        8.1.3 Others
    8.2 Preventive Medications
        8.2.1 Blood pressure-lowering Medications
        8.2.2 Anticonvulsant Drugs
        8.2.3 Calcitonin gene-related Peptide (CGRP) Antagonists
        8.2.4 Other Preventative Therapies
9. Anti-Migraine Drugs Market – By End User Type
    9.1 Females
    9.2 Males
10. Anti-Migraine Drugs Market – By Route of Administration
    10.1 Oral & Nasal
    10.2 Injectables
11. Anti-Migraine Drugs Market – By Distribution Channel
    11.1 Pharmaceutical stores
    11.2 Online Stores
    11.3 Others
12. Anti-Migraine Drugs Market - By Geography
    12.1 North America
        12.1.1 U.S.
        12.1.2 Canada
        12.1.3 Mexico
    12.2 Europe
        12.2.1 U.K.
        12.2.2 Germany
        12.2.3 France
        12.2.4 Italy
        12.2.5 Spain
        12.2.6 Russia
        12.2.7 Rest of Europe
    12.3 Asia-Pacific
        12.3.1 China
        12.3.2 India
        12.3.3 Japan
        12.3.4 South Korea
        12.3.5 Australia & New Zealand
        12.3.6 Rest of Asia-Pacific
    12.4 South America
        12.4.1 Brazil
        12.4.2 Argentina
        12.4.3 Rest of South America
    12.5 Rest of the World
        12.5.1 Middle East
        12.5.2 Africa
13. Anti-Migraine Drugs Market - Entropy
14. Anti-Migraine Drugs Market – Industry/Segment Competition Landscape Premium 
    14.1 Market Share Analysis
        14.1.1 Global Market Share – Key Companies
        14.1.2 Market Share by Region – Key companies
        14.1.3 Market Share by Countries – Key Companies
    14.2 Best Practices for Companies
    14.3 Competition Matrix
15. Anti-Migraine Drugs Market – Key Company List by Country Premium Premium
16. Anti-Migraine Drugs Market Company Analysis
    16.1 Company 1
    16.2 Company 2
    16.3 Company 3
    16.4 Company 4
    16.5 Company 5
    16.6 Company 6
    16.7 Company 7
    16.8 Company 8
    16.9 Company 9
    16.10 Company 10
"*Financials for private companies would be provided on a best efforts basis”.
List of Tables
Table 1: Anti-Migraine Drugs Market Analysis Overview 2021-2026
Table 2: Anti-Migraine Drugs Market Analysis Leader Analysis 2018-2019 (US$)
Table 3: Anti-Migraine Drugs Market Analysis Product Analysis 2018-2019 (US$)
Table 4: Anti-Migraine Drugs Market Analysis End User Analysis 2018-2019 (US$)
Table 5: Anti-Migraine Drugs Market Analysis Patent Analysis 2013-2018* (US$)
Table 6: Anti-Migraine Drugs Market Analysis Financial Analysis 2018-2019 (US$)
Table 7: Anti-Migraine Drugs Market Analysis Driver Analysis 2018-2019 (US$)
Table 8: Anti-Migraine Drugs Market Analysis Challenges Analysis 2018-2019 (US$)
Table 9: Anti-Migraine Drugs Market Analysis Constraint Analysis 2018-2019 (US$)
Table 10: Anti-Migraine Drugs Market Analysis Supplier Bargaining Power Analysis 2018-2019 (US$)
Table 11: Anti-Migraine Drugs Market Analysis Buyer Bargaining Power Analysis 2018-2019 (US$)
Table 12: Anti-Migraine Drugs Market Analysis Threat of Substitutes Analysis 2018-2019 (US$)
Table 13: Anti-Migraine Drugs Market Analysis Threat of New Entrants Analysis 2018-2019 (US$)
Table 14: Anti-Migraine Drugs Market Analysis Degree of Competition Analysis 2018-2019 (US$)
Table 15: Anti-Migraine Drugs Market Analysis Value Chain Analysis 2018-2019 (US$)
Table 16: Anti-Migraine Drugs Market Analysis Pricing Analysis 2021-2026 (US$)
Table 17: Anti-Migraine Drugs Market Analysis Opportunities Analysis 2021-2026 (US$)
Table 18: Anti-Migraine Drugs Market Analysis Product Life Cycle Analysis 2021-2026 (US$)
Table 19: Anti-Migraine Drugs Market Analysis Supplier Analysis 2018-2019 (US$)
Table 20: Anti-Migraine Drugs Market Analysis Distributor Analysis 2018-2019 (US$)
Table 21: Anti-Migraine Drugs Market Analysis Trend Analysis 2018-2019 (US$)
Table 22: Anti-Migraine Drugs Market Analysis Size 2018 (US$)
Table 23: Anti-Migraine Drugs Market Analysis Forecast Analysis 2021-2026 (US$)
Table 24: Anti-Migraine Drugs Market Analysis Sales Forecast Analysis 2021-2026 (Units)
Table 25: Anti-Migraine Drugs Market Analysis, Revenue & Volume, By Drugs Type, 2021-2026 ($)
Table 26: Anti-Migraine Drugs Market Analysis By Drugs Type, Revenue & Volume,By Triptans, 2021-2026 ($)
Table 27: Anti-Migraine Drugs Market Analysis By Drugs Type, Revenue & Volume,By Ergot Alkaloids, 2021-2026 ($)
Table 28: Anti-Migraine Drugs Market Analysis By Drugs Type, Revenue & Volume,By Sumatriptan, 2021-2026 ($)
Table 29: Anti-Migraine Drugs Market Analysis By Drugs Type, Revenue & Volume,By Zolmitriptan, 2021-2026 ($)
Table 30: Anti-Migraine Drugs Market Analysis By Drugs Type, Revenue & Volume,By Rizatriptan, 2021-2026 ($)
Table 31: North America Anti-Migraine Drugs Market Analysis, Revenue & Volume,By Drugs Type, 2021-2026 ($)
Table 32: South america Anti-Migraine Drugs Market Analysis, Revenue & Volume,By Drugs Type, 2021-2026 ($)
Table 33: Europe Anti-Migraine Drugs Market Analysis, Revenue & Volume,By Drugs Type, 2021-2026 ($)
Table 34: APAC Anti-Migraine Drugs Market Analysis, Revenue & Volume,By Drugs Type, 2021-2026 ($)
Table 35: Middle East & Africa Anti-Migraine Drugs Market Analysis, Revenue & Volume,By Drugs Type, 2021-2026 ($)
Table 36: Russia Anti-Migraine Drugs Market Analysis, Revenue & Volume,By Drugs Type, 2021-2026 ($)
Table 37: Israel Anti-Migraine Drugs Market Analysis, Revenue & Volume,By Drugs Type, 2021-2026 ($)
Table 38: Top Companies 2018 (US$)Anti-Migraine Drugs Market Analysis, Revenue & Volume
Table 39: Product Launch 2018-2019Anti-Migraine Drugs Market Analysis, Revenue & Volume
Table 40: Mergers & Acquistions 2018-2019Anti-Migraine Drugs Market Analysis, Revenue & Volume

List of Figures
Figure 1: Overview of Anti-Migraine Drugs Market Analysis 2021-2026
Figure 2: Market Share Analysis for Anti-Migraine Drugs Market Analysis 2018 (US$)
Figure 3: Product Comparison in Anti-Migraine Drugs Market Analysis 2018-2019 (US$)
Figure 4: End User Profile for Anti-Migraine Drugs Market Analysis 2018-2019 (US$)
Figure 5: Patent Application and Grant in Anti-Migraine Drugs Market Analysis 2013-2018* (US$)
Figure 6: Top 5 Companies Financial Analysis in Anti-Migraine Drugs Market Analysis 2018-2019 (US$)
Figure 7: Market Entry Strategy in Anti-Migraine Drugs Market Analysis 2018-2019
Figure 8: Ecosystem Analysis in Anti-Migraine Drugs Market Analysis2018
Figure 9: Average Selling Price in Anti-Migraine Drugs Market Analysis 2021-2026
Figure 10: Top Opportunities in Anti-Migraine Drugs Market Analysis 2018-2019
Figure 11: Market Life Cycle Analysis in Anti-Migraine Drugs Market Analysis
Figure 12: Global By Drugs Type Anti-Migraine Drugs Market Analysis Revenue, 2021-2026 ($)
Figure 13: Global Anti-Migraine Drugs Market Analysis - By Geography
Figure 14: Global Anti-Migraine Drugs Market Analysis Value & Volume, By Geography, 2021-2026 ($) 
Figure 15: Global Anti-Migraine Drugs Market Analysis CAGR, By Geography, 2021-2026 (%)
Figure 16: North America Anti-Migraine Drugs Market Analysis Value & Volume, 2021-2026 ($)
Figure 17: US Anti-Migraine Drugs Market Analysis Value & Volume, 2021-2026 ($)
Figure 18: US GDP and Population, 2018-2019 ($)
Figure 19: US GDP – Composition of 2018, By Sector of Origin
Figure 20: US Export and Import Value & Volume, 2018-2019 ($)
Figure 21: Canada Anti-Migraine Drugs Market Analysis Value & Volume, 2021-2026 ($)
Figure 22: Canada GDP and Population, 2018-2019 ($)
Figure 23: Canada GDP – Composition of 2018, By Sector of Origin
Figure 24: Canada Export and Import Value & Volume, 2018-2019 ($)
Figure 25: Mexico Anti-Migraine Drugs Market Analysis Value & Volume, 2021-2026 ($)
Figure 26: Mexico GDP and Population, 2018-2019 ($)
Figure 27: Mexico GDP – Composition of 2018, By Sector of Origin
Figure 28: Mexico Export and Import Value & Volume, 2018-2019 ($)
Figure 29: South America Anti-Migraine Drugs Market Analysis Value & Volume, 2021-2026 ($)
Figure 30: Brazil Anti-Migraine Drugs Market Analysis Value & Volume, 2021-2026 ($)
Figure 31: Brazil GDP and Population, 2018-2019 ($)
Figure 32: Brazil GDP – Composition of 2018, By Sector of Origin
Figure 33: Brazil Export and Import Value & Volume, 2018-2019 ($)
Figure 34: Venezuela Anti-Migraine Drugs Market Analysis Value & Volume, 2021-2026 ($)
Figure 35: Venezuela GDP and Population, 2018-2019 ($)
Figure 36: Venezuela GDP – Composition of 2018, By Sector of Origin
Figure 37: Venezuela Export and Import Value & Volume, 2018-2019 ($)
Figure 38: Argentina Anti-Migraine Drugs Market Analysis Value & Volume, 2021-2026 ($)
Figure 39: Argentina GDP and Population, 2018-2019 ($)
Figure 40: Argentina GDP – Composition of 2018, By Sector of Origin
Figure 41: Argentina Export and Import Value & Volume, 2018-2019 ($)
Figure 42: Ecuador Anti-Migraine Drugs Market Analysis Value & Volume, 2021-2026 ($)
Figure 43: Ecuador GDP and Population, 2018-2019 ($)
Figure 44: Ecuador GDP – Composition of 2018, By Sector of Origin
Figure 45: Ecuador Export and Import Value & Volume, 2018-2019 ($)
Figure 46: Peru Anti-Migraine Drugs Market Analysis Value & Volume, 2021-2026 ($)
Figure 47: Peru GDP and Population, 2018-2019 ($)
Figure 48: Peru GDP – Composition of 2018, By Sector of Origin
Figure 49: Peru Export and Import Value & Volume, 2018-2019 ($)
Figure 50: Colombia Anti-Migraine Drugs Market Analysis Value & Volume, 2021-2026 ($)
Figure 51: Colombia GDP and Population, 2018-2019 ($)
Figure 52: Colombia GDP – Composition of 2018, By Sector of Origin
Figure 53: Colombia Export and Import Value & Volume, 2018-2019 ($)
Figure 54: Costa Rica Anti-Migraine Drugs Market Analysis Value & Volume, 2021-2026 ($)
Figure 55: Costa Rica GDP and Population, 2018-2019 ($)
Figure 56: Costa Rica GDP – Composition of 2018, By Sector of Origin
Figure 57: Costa Rica Export and Import Value & Volume, 2018-2019 ($)
Figure 58: Europe Anti-Migraine Drugs Market Analysis Value & Volume, 2021-2026 ($)
Figure 59: U.K Anti-Migraine Drugs Market Analysis Value & Volume, 2021-2026 ($)
Figure 60: U.K GDP and Population, 2018-2019 ($)
Figure 61: U.K GDP – Composition of 2018, By Sector of Origin
Figure 62: U.K Export and Import Value & Volume, 2018-2019 ($)
Figure 63: Germany Anti-Migraine Drugs Market Analysis Value & Volume, 2021-2026 ($)
Figure 64: Germany GDP and Population, 2018-2019 ($)
Figure 65: Germany GDP – Composition of 2018, By Sector of Origin
Figure 66: Germany Export and Import Value & Volume, 2018-2019 ($)
Figure 67: Italy Anti-Migraine Drugs Market Analysis Value & Volume, 2021-2026 ($)
Figure 68: Italy GDP and Population, 2018-2019 ($)
Figure 69: Italy GDP – Composition of 2018, By Sector of Origin
Figure 70: Italy Export and Import Value & Volume, 2018-2019 ($)
Figure 71: France Anti-Migraine Drugs Market Analysis Value & Volume, 2021-2026 ($)
Figure 72: France GDP and Population, 2018-2019 ($)
Figure 73: France GDP – Composition of 2018, By Sector of Origin
Figure 74: France Export and Import Value & Volume, 2018-2019 ($)
Figure 75: Netherlands Anti-Migraine Drugs Market Analysis Value & Volume, 2021-2026 ($)
Figure 76: Netherlands GDP and Population, 2018-2019 ($)
Figure 77: Netherlands GDP – Composition of 2018, By Sector of Origin
Figure 78: Netherlands Export and Import Value & Volume, 2018-2019 ($)
Figure 79: Belgium Anti-Migraine Drugs Market Analysis Value & Volume, 2021-2026 ($)
Figure 80: Belgium GDP and Population, 2018-2019 ($)
Figure 81: Belgium GDP – Composition of 2018, By Sector of Origin
Figure 82: Belgium Export and Import Value & Volume, 2018-2019 ($)
Figure 83: Spain Anti-Migraine Drugs Market Analysis Value & Volume, 2021-2026 ($)
Figure 84: Spain GDP and Population, 2018-2019 ($)
Figure 85: Spain GDP – Composition of 2018, By Sector of Origin
Figure 86: Spain Export and Import Value & Volume, 2018-2019 ($)
Figure 87: Denmark Anti-Migraine Drugs Market Analysis Value & Volume, 2021-2026 ($)
Figure 88: Denmark GDP and Population, 2018-2019 ($)
Figure 89: Denmark GDP – Composition of 2018, By Sector of Origin
Figure 90: Denmark Export and Import Value & Volume, 2018-2019 ($)
Figure 91: APAC Anti-Migraine Drugs Market Analysis Value & Volume, 2021-2026 ($)
Figure 92: China Anti-Migraine Drugs Market Analysis Value & Volume, 2021-2026
Figure 93: China GDP and Population, 2018-2019 ($)
Figure 94: China GDP – Composition of 2018, By Sector of Origin
Figure 95: China Export and Import Value & Volume, 2018-2019 ($)Anti-Migraine Drugs Market Analysis China Export and Import Value & Volume, 2018-2019 ($)
Figure 96: Australia Anti-Migraine Drugs Market Analysis Value & Volume, 2021-2026 ($)
Figure 97: Australia GDP and Population, 2018-2019 ($)
Figure 98: Australia GDP – Composition of 2018, By Sector of Origin
Figure 99: Australia Export and Import Value & Volume, 2018-2019 ($)
Figure 100: South Korea Anti-Migraine Drugs Market Analysis Value & Volume, 2021-2026 ($)
Figure 101: South Korea GDP and Population, 2018-2019 ($)
Figure 102: South Korea GDP – Composition of 2018, By Sector of Origin
Figure 103: South Korea Export and Import Value & Volume, 2018-2019 ($)
Figure 104: India Anti-Migraine Drugs Market Analysis Value & Volume, 2021-2026 ($)
Figure 105: India GDP and Population, 2018-2019 ($)
Figure 106: India GDP – Composition of 2018, By Sector of Origin
Figure 107: India Export and Import Value & Volume, 2018-2019 ($)
Figure 108: Taiwan Anti-Migraine Drugs Market Analysis Value & Volume, 2021-2026 ($)
Figure 109: Taiwan GDP and Population, 2018-2019 ($)
Figure 110: Taiwan GDP – Composition of 2018, By Sector of Origin
Figure 111: Taiwan Export and Import Value & Volume, 2018-2019 ($)
Figure 112: Malaysia Anti-Migraine Drugs Market Analysis Value & Volume, 2021-2026 ($)
Figure 113: Malaysia GDP and Population, 2018-2019 ($)
Figure 114: Malaysia GDP – Composition of 2018, By Sector of Origin
Figure 115: Malaysia Export and Import Value & Volume, 2018-2019 ($)
Figure 116: Hong Kong Anti-Migraine Drugs Market Analysis Value & Volume, 2021-2026 ($)
Figure 117: Hong Kong GDP and Population, 2018-2019 ($)
Figure 118: Hong Kong GDP – Composition of 2018, By Sector of Origin
Figure 119: Hong Kong Export and Import Value & Volume, 2018-2019 ($)
Figure 120: Middle East & Africa Anti-Migraine Drugs Market AnalysisMiddle East & Africa 3D Printing Market Value & Volume, 2021-2026 ($)
Figure 121: Russia Anti-Migraine Drugs Market Analysis Value & Volume, 2021-2026 ($)
Figure 122: Russia GDP and Population, 2018-2019 ($)
Figure 123: Russia GDP – Composition of 2018, By Sector of Origin
Figure 124: Russia Export and Import Value & Volume, 2018-2019 ($)
Figure 125: Israel Anti-Migraine Drugs Market Analysis Value & Volume, 2021-2026 ($)
Figure 126: Israel GDP and Population, 2018-2019 ($)
Figure 127: Israel GDP – Composition of 2018, By Sector of Origin
Figure 128: Israel Export and Import Value & Volume, 2018-2019 ($)
Figure 129: Entropy Share, By Strategies, 2018-2019* (%)Anti-Migraine Drugs Market Analysis
Figure 130: Developments, 2018-2019*Anti-Migraine Drugs Market Analysis
Figure 131: Company 1 Anti-Migraine Drugs Market Analysis Net Revenue, By Years, 2018-2019* ($)
Figure 132: Company 1 Anti-Migraine Drugs Market Analysis Net Revenue Share, By Business segments, 2018 (%)
Figure 133: Company 1 Anti-Migraine Drugs Market Analysis Net Sales Share, By Geography, 2018 (%)
Figure 134: Company 2 Anti-Migraine Drugs Market Analysis Net Revenue, By Years, 2018-2019* ($)
Figure 135: Company 2 Anti-Migraine Drugs Market Analysis Net Revenue Share, By Business segments, 2018 (%)
Figure 136: Company 2 Anti-Migraine Drugs Market Analysis Net Sales Share, By Geography, 2018 (%)
Figure 137: Company 3Anti-Migraine Drugs Market Analysis Net Revenue, By Years, 2018-2019* ($)
Figure 138: Company 3Anti-Migraine Drugs Market Analysis Net Revenue Share, By Business segments, 2018 (%)
Figure 139: Company 3Anti-Migraine Drugs Market Analysis Net Sales Share, By Geography, 2018 (%)
Figure 140: Company 4 Anti-Migraine Drugs Market Analysis Net Revenue, By Years, 2018-2019* ($)
Figure 141: Company 4 Anti-Migraine Drugs Market Analysis Net Revenue Share, By Business segments, 2018 (%)
Figure 142: Company 4 Anti-Migraine Drugs Market Analysis Net Sales Share, By Geography, 2018 (%)
Figure 143: Company 5 Anti-Migraine Drugs Market Analysis Net Revenue, By Years, 2018-2019* ($)
Figure 144: Company 5 Anti-Migraine Drugs Market Analysis Net Revenue Share, By Business segments, 2018 (%)
Figure 145: Company 5 Anti-Migraine Drugs Market Analysis Net Sales Share, By Geography, 2018 (%)
Figure 146: Company 6 Anti-Migraine Drugs Market Analysis Net Revenue, By Years, 2018-2019* ($)
Figure 147: Company 6 Anti-Migraine Drugs Market Analysis Net Revenue Share, By Business segments, 2018 (%)
Figure 148: Company 6 Anti-Migraine Drugs Market Analysis Net Sales Share, By Geography, 2018 (%)
Figure 149: Company 7 Anti-Migraine Drugs Market Analysis Net Revenue, By Years, 2018-2019* ($)
Figure 150: Company 7 Anti-Migraine Drugs Market Analysis Net Revenue Share, By Business segments, 2018 (%)
Figure 151: Company 7 Anti-Migraine Drugs Market Analysis Net Sales Share, By Geography, 2018 (%)
Figure 152: Company 8 Anti-Migraine Drugs Market Analysis Net Revenue, By Years, 2018-2019* ($)
Figure 153: Company 8 Anti-Migraine Drugs Market Analysis Net Revenue Share, By Business segments, 2018 (%)
Figure 154: Company 8 Anti-Migraine Drugs Market Analysis Net Sales Share, By Geography, 2018 (%)
Figure 155: Company 9 Anti-Migraine Drugs Market Analysis Net Revenue, By Years, 2018-2019* ($)
Figure 156: Company 9 Anti-Migraine Drugs Market Analysis Net Revenue Share, By Business segments, 2018 (%)
Figure 157: Company 9 Anti-Migraine Drugs Market Analysis Net Sales Share, By Geography, 2018 (%)
Figure 158: Company 10 Anti-Migraine Drugs Market Analysis Net Revenue, By Years, 2018-2019* ($)
Figure 159: Company 10 Anti-Migraine Drugs Market Analysis Net Revenue Share, By Business segments, 2018 (%)
Figure 160: Company 10 Anti-Migraine Drugs Market Analysis Net Sales Share, By Geography, 2018 (%)
Figure 161: Company 11 Anti-Migraine Drugs Market Analysis Net Revenue, By Years, 2018-2019* ($)
Figure 162: Company 11 Anti-Migraine Drugs Market Analysis Net Revenue Share, By Business segments, 2018 (%)
Figure 163: Company 11 Anti-Migraine Drugs Market Analysis Net Sales Share, By Geography, 2018 (%)
Figure 164: Company 12 Anti-Migraine Drugs Market Analysis Net Revenue, By Years, 2018-2019* ($)
Figure 165: Company 12 Anti-Migraine Drugs Market Analysis Net Revenue Share, By Business segments, 2018 (%)
Figure 166: Company 12 Anti-Migraine Drugs Market Analysis Net Sales Share, By Geography, 2018 (%)
Figure 167: Company 13Anti-Migraine Drugs Market Analysis Net Revenue, By Years, 2018-2019* ($)
Figure 168: Company 13Anti-Migraine Drugs Market Analysis Net Revenue Share, By Business segments, 2018 (%)
Figure 169: Company 13Anti-Migraine Drugs Market Analysis Net Sales Share, By Geography, 2018 (%)
Figure 170: Company 14 Anti-Migraine Drugs Market Analysis Net Revenue, By Years, 2018-2019* ($)
Figure 171: Company 14 Anti-Migraine Drugs Market Analysis Net Revenue Share, By Business segments, 2018 (%)
Figure 172: Company 14 Anti-Migraine Drugs Market Analysis Net Sales Share, By Geography, 2018 (%)
Figure 173: Company 15 Anti-Migraine Drugs Market Analysis Net Revenue, By Years, 2018-2019* ($)
Figure 174: Company 15 Anti-Migraine Drugs Market Analysis Net Revenue Share, By Business segments, 2018 (%)
Figure 175: Company 15 Anti-Migraine Drugs Market Analysis Net Sales Share, By Geography, 2018 (%)